NRx Pharmaceuticals’ (NRXP) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a report released on Monday,Benzinga reports. The brokerage currently has a $31.00 price objective on the stock.

Several other research firms have also recently issued reports on NRXP. Ascendiant Capital Markets upped their target price on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. HC Wainwright restated a “buy” rating and set a $19.00 price objective on shares of NRx Pharmaceuticals in a research report on Monday, November 25th. Finally, EF Hutton Acquisition Co. I raised shares of NRx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 21st.

NRx Pharmaceuticals Trading Down 19.3 %

NRx Pharmaceuticals stock opened at $3.76 on Monday. The firm has a market cap of $45.47 million, a price-to-earnings ratio of -1.76 and a beta of 1.08. NRx Pharmaceuticals has a 12 month low of $1.10 and a 12 month high of $7.33. The stock has a fifty day simple moving average of $1.58 and a two-hundred day simple moving average of $1.78.

Insider Buying and Selling at NRx Pharmaceuticals

In other NRx Pharmaceuticals news, Chairman Jonathan C. Javitt bought 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The stock was bought at an average cost of $1.17 per share, for a total transaction of $46,800.00. Following the completion of the transaction, the chairman now owns 84,634 shares of the company’s stock, valued at $99,021.78. This represents a 89.62 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 19.00% of the company’s stock.

Institutional Investors Weigh In On NRx Pharmaceuticals

An institutional investor recently bought a new position in NRx Pharmaceuticals stock. Anson Funds Management LP purchased a new stake in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 142,525 shares of the company’s stock, valued at approximately $241,000. Anson Funds Management LP owned 1.33% of NRx Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.